American Medical Systems claims US first for ethanol prostate study:
This article was originally published in Clinica
American Medical Systems (AMS) is to begin a US clinical trial of its ProstaJect ethanol injection system for treating benign prostatic hyperplasia. The Minneapolis, Minnesota company plans to start enrolling patients at 15 centres early this year. AMS president and CEO Douglas Kohrs says that the clinical study is the first in the US to assess the use of ethanol as a means of ablating cells in the prostate gland.